Drug Discovery

New PET Imaging Monitors Cancer and Cardiac Inflammation
Research & Development New PET Imaging Monitors Cancer and Cardiac Inflammation

The delicate balance between eradicating a life-threatening malignancy and preserving the fundamental structural integrity of the human heart has long remained one of the most perilous tightropes in modern medicine. While the introduction of immune checkpoint inhibitors (ICIs) has fundamentally

Can Triplet Therapy Transform BRAF-Mutant Colorectal Cancer?
Research & Development Can Triplet Therapy Transform BRAF-Mutant Colorectal Cancer?

Patients diagnosed with metastatic colorectal cancer carrying the BRAF V600E mutation have long navigated a clinical landscape where conventional chemotherapy often fails to provide lasting control over their disease. This specific genetic signature, found in approximately ten percent of metastatic

Can Unbiased Spatial Proteomics Reveal Hidden Drug Targets?
Tech & Innovation Can Unbiased Spatial Proteomics Reveal Hidden Drug Targets?

The pharmaceutical industry has long grappled with the high failure rates of clinical trials that often stem from a fundamental lack of understanding regarding the intricate spatial relationships within human tissues. While genomic and transcriptomic profiling provided a foundational blueprint for

Genetic Map of Feline Cancer Reveals Links to Human Health
Research & Development Genetic Map of Feline Cancer Reveals Links to Human Health

The recent publication of a comprehensive feline cancer genomic atlas provides an unprecedented view into the molecular commonalities that link domestic cats and humans, offering transformative insights into how oncogenic processes evolve across mammalian species. This mapping effort involved the

Perioperative Apalutamide vs. Standard ADT: A Comparative Analysis
Research & Development Perioperative Apalutamide vs. Standard ADT: A Comparative Analysis

The daunting reality of high-risk localized prostate cancer is that surgical intervention often feels like an incomplete solution, especially when half of patients face a biological recurrence within just five years of their primary treatment. This aggressive form of the disease, which accounts for

Can Daraxonrasib Double Pancreatic Cancer Survival?
Research & Development Can Daraxonrasib Double Pancreatic Cancer Survival?

The landscape of pancreatic cancer treatment has long been defined by limited options and daunting prognoses, making any significant clinical breakthrough a cause for global attention. Ivan Kairatov, a veteran Biopharma expert with a distinguished career in research and development, joins us to

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later